Mathematical model of BCG immunotherapy in superficial bladder cancer

Bulletin of Mathematical Biology

Volumn 69, Issue 6, 2007, Pages 1847-1870

  Bunimovich Mendrazitsky, Svetlana ^a   Shochat, Eliezer ^b   Stone, Lewi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Bladder cancer; Cytotoxic cells; Immune response; Nonlinear dynamics

Indexed keywords

BCG VACCINE;

ACTIVE IMMUNIZATION; ANIMAL; ARTICLE; BIOLOGICAL MODEL; BLADDER TUMOR; HUMAN; IMMUNOLOGY; IN VITRO STUDY; MATHEMATICS; MOUSE; STATISTICAL MODEL; TRANSITIONAL CELL CARCINOMA;

ANIMALS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; HUMANS; IMMUNOTHERAPY, ACTIVE; LOGISTIC MODELS; MATHEMATICS; MICE; MODELS, IMMUNOLOGICAL; URINARY BLADDER NEOPLASMS;

MYCOBACTERIUM BOVIS; MYCOBACTERIUM BOVIS BCG;

EID: 34547657511     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-007-9195-z     Document Type: Article

References (42)

1. Alexandroff, A.B., Jackson, A.M., O'Donnell, M.A., James, K., 1999. BCG immunotherapy of bladder cancer: 20 years on. Lancet 353, 1689.
2. Andius, P., Holmang, S., 2004. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int. 93(7), 980-984.
3. Aranha, O., Wood, D.P., Sarkar, F.H., 2000. Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin. Cancer Res. 6, 891-900.
4. Archuleta, J., Mullens, P., Primm, T.P., 2002. The relationship of temperature to desiccation and starvation tolerance of the Mycobacterium avium complex. Arch. Microbiol. 178, 311-314.
5. Banks, R.B., 1994. Growth and Diffusion Phenomena. Springer, Berlin.
6. Bevers, R.F.M., Kurth, K.H., Schamhart, D.H.J., 2004. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br. J. Cancer 91, 607-612.
7. Bohle, A., Brandau, S., 2003. Immune mechanisms in bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. J. Urol. 170, 964-969.
8. Bowyer, L., Hall, R.R., Reading, J., Marsh, M.M., 1995. The persistence of bacille Calmette-Guérin in the bladder after intravesical treatment for bladder cancer. Br. J. Urol. 75(2), 188-192.
9. Bru, A., Albertos, S., Garcia-Asenjo, J.A.L., Bru, I., 2004. Pinning of tumoral growth by enhancement of the immune response. Phys. Rev. Lett. 11 92(23), 238101.
10. Chen, F., Zhang, G., Iwamoto, Y., See, W., 2005. BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. BMC Urol. 5, 8.
11. Cheng, C.W., Ng, M.T., Chan, S.Y., Sun, W.H., 2004. Low dose BCG as adjuvant therapy for superficial bladder cancer and literature review. ANZ J. Surg. 74(7), 569-572.
12. Chiou, R.K., Dalrymple, G.V., Baranowska-Kortylewicz, J., Holdeman, K.P., Schneiderman, M.H., Harrison, K.A., Taylor, R.J., 1999. Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer. J. Urol. 162(1), 58-62.
13. Chopin, D., Gattegno, B., 2002. Superficial bladder tumors. Eur. Urol. 42, 533-541.
14. De Boer, E.C., Bevers, R.F., Kurth, K.H., Schamhart, D.H., 1996. Double fluorescent flow cytometric assessment of bacterial internalization and binding by epithelial cells. Cytometry 25, 381-387.
15. De Pillis, L.G., Radunskaya, A.E., Wiseman, C.L., 2005. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 65(17), 7950-7958.
16. De Pillis, L.G., Gu, W., Radunskaya, A.E., 2006. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. J. Theor. Biol. 238, 841-862.
17. De Reijke, T.M., De Boer, E.C., Kurth, K.H., Schamhart, D.H., 1999. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations? J. Urol. 161(1), 67-71.
18. Dumey, N., Mongiat-Artus, P., Devauchelle, P., Lesourd, A., Cotard, J.P., Le Duc, A., Marty, M., Cussenot, O., Cohen-Haguenauer, O., 2005. In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells. Eur. Urol. 47(2), 257-263.
19. Durek, C., Brandau, S., Ulmer, A.J., Flad, H.D., Jocham, D., Bohle, A., 1999. Bacillus Calmette-Guerin (BCG) and 3D tumors: an in vitro model for the study of adhesion and invasion. J. Urol. 162, 600-605.
20. Elkabani, M., Greene, J.N., Vincent, A.L., VanHook, S., Sandin, R.L., 2000. Disseminated Mycobacterium bovis after intravesicular bacillus Calmette-Guérin treatments for bladder cancer. Cancer Control 7(5), 476-481.
21. Franks, S.J., Byrne, H.M., King, J.R., Underwood, J.C., Lewis, C.E., 2003. Modelling the early growth of ductal carcinoma in situ of the breast. J. Math. Biol. 47(5), 424-452.
22. Hale, J.K., Kocak, H., 1991. Dynamics and Bifurcations. Springer, Berlin.
23. Kaasinen, E., Rintala, E., Pere, A.K., Kallio, J., Puolakka, V.M., Liukkonen, T., Tuhkanen, K., 2000. Weekly mitomycin C followed by monthly bacillus Calmette-Guérin or alternating monthly interferon-alpha2B and bacillus Calmette-Guérin for prophylaxis of recurrent papillary superficial bladder carcinoma. J. Urol. 164(1):47-52.
24. Kassouf, W., Kamat, A.M., 2004. Current state of immunotherapy for bladder cancer. Expert. Rev. Anticancer Ther. 4(6), 1037-1046.
25. Kim, J.C., Steinberg, G.D., 2001. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. J. Urol. 165(3), 745-756.
26. Kirschner, D., Panetta, J., 1998. Modelling immunotherapy of the tumor-immune interaction. J. Math. Biol. 37(3), 235-252.
27. Kuznetsov, V.A., Makalkin, I.A., Taylor, M.A., Perelson, A.S., 1994. Nonlinear dynamics of immunogenic tumours: parameter estimation and global bifurcation analysis. Bull. Math. Biol. 56, 295-321.
28. Lamm, D.L., Mcgee, W.R., Hale, K., 2005. Bladder cancer: current optimal intravesical treatment. Urol. Nurs. 25(5), 323-332.
29. Lakshmikantham, V., Bainov, D.D., Simeonov, P.S., 1989. Theory of Impulsive Differential Equations. World Scientific, Singapore.
30. Lämmle, M., Beer, A., Settles, M., Hanning, C., Schwaibold, H., Drews, C., 2002. Reliability of MR imaging-based virtual cystoscopy in the diagnosis of cancer of the urinary bladder. Am. J. Roentgenol. 178, 1483-1488.
31. Limas, C., Bigle, A., Bair, R., Bernhart, P., Reddy, P., 1993. Proliferative activity of urothelial neoplasms: comparison of BrdU incorporation, Ki67 expression, and nucleolar organiser regions. J. Clin. Pathol. 46(2), 159-165.
32. Modlich, O., Prisack, H.B., Pitschke, G., Ramp, U., Ackermann, R., Bojar, H., 2004. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin. Cancer Res. 10(10), 3410-3421.
33. Morales, A., Eidinger, D., Bruce, A.W., 1976. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J. Urol. 116, 180.
34. Nseyo, U.O., Lamm, D.L., 1997. Immunotherapy of bladder cancer. Semin. Surg. Oncol. 13, 342-349.
35. Papac, R.J., 1996. Spontaneous regression of cancer. Cancer Treat. Rev. 22(6), 395-423.
36. Patard, J.J., Saint, F., Velotti, F., Abbou, C.C., Chopin, D.K., 1998. Immune response following intravesical bacillus Calmette-Guérin instillations in superficial bladder cancer: a review. Urol. Res. 26(3), 155-159.
37. Press, W., Teukolsky, T., Vetterling, W.T., Flannery, B.P., 1992. Numerical Recipes. Cambridge University Press, New York.
38. Schenk-Braat, E.A.M., Bangma, C.H., 2005. Immunotherapy for superficial bladder cancer. Cancer Immunol. Immunother. 54(5), 414-423.
39. Shochat, E., Hart, D., Agur, Z., 1999. Using computer simulations for evaluating the efficacy of breast cancer chemotherapy protocols. Math. Models Meth. Appl. Sci. 9(4), 599-615.
40. Spratt, J.A., Von Fournier, D., Spratt, J.S., Weber, E.E., 1993. Decelerating growth and human breast cancer. Cancer 71(6), 2013-2019.
41. Swanson, K.R., Bridge, C., Murray, J.D., Alvord, E.C., 2003. Virtual and real brain tumors:using mathematical modeling to quantify glioma growth and invasion. J. Neurol. Sci. 216, 1-10.
42. Wigginton, J., Kirschner, D., 2001. A model to predict cell-mediated immune regulatory mechanisms during human infection with mycobacterium tuberculosis. J. Immunol. 166, 1951-1967.